Supply & Delivery
Supply & Delivery

CAR-T Supply and Delivery Process

From leukapheresis to infusion, our fully coordinated end-to-end process ensures the safe, timely, and high-quality delivery of CAR-T products
< 21 Days

Average Vein-to-Vein Time(from leukapheresis to infusion)

100%

On-Time Delivery Rate

100%

Temperature Compliance Rate During Transportation

99%

Manufacturing Success Rate

* Since its listing

Patient Assessment & Order Confirmation
Patient Assessment & Order Confirmation

● Assess patient eligibility. 
● Confirm the Carteyva® treatment plan. 
● Complete product ordering. 

01
Pre-Apheresis Assessment
Pre-Apheresis Assessment

● Schedule the apheresis collection. 
● Submit and confirm the apheresis request. 
● Assess treatment status and pre-collection requirements.

02
Apheresis Collection
Apheresis Collection

● Verify equipment, personnel, and documentation.

● Collect and package PBMCs under cold-chain conditions. 

● Record collection data in the COI system. 

03
Pre-Shipment Cold Chain Verification
Pre-Shipment Cold Chain Verification

● Verify APH packaging procedures. 
● Confirm logistics personnel and documentation. 
● Enter shipment information into the COI system.

04
CAR-T Manufacturing Updates
CAR-T Manufacturing Updates

● Track manufacturing progress. 
● Monitor quality testing and product release. 
● Update packaging and product information. 

05
Pre-Infusion Preparation
Pre-Infusion Preparation

● Confirm infusion application and schedule. 
● Complete lymphodepletion chemotherapy. 
● Provide patient education and COI documentation.

06
Cryogenic Cold-Chain Transportation
Cryogenic Cold-Chain Transportation

● Track product shipping status. 
● Confirm product receipt at the treatment center. 
● Complete COI documentation. 

07
Infusion
Infusion

● Verify patient, product, and infusion documentation. 
● Prepare materials and confirm the infusion bag. 
● Complete infusion and update COI records. 

08
Post-Infusion Monitoring
Post-Infusion Monitoring

● Monitor infusion-related adverse events. 
● Continue on-site and remote monitoring. 
● Provide long-term follow-up services.
Email:PV@jwtherapeutics.com

09
Terminology Notes
  • APH (Apheresis): Refers to the starting material of patient cells obtained through an apheresis procedure.
  • COI (Chain of Identity): A system used to ensure the link in identity and traceability between a patient and their corresponding cell product throughout the processes of collection, manufacturing, transport, and administration.
  • DTP (Direct to Patient): A specialized pharmacy service model that involves the sale, delivery, and associated pharmaceutical services for prescription medications directly to patients.
End-to-End Control
End-to-End Control

End-to-end in-house management from leukapheresis collection to patient infusion, ensuring full control over critical processes.

End-to-End Traceability
End-to-End Traceability

The Chain of Identity (COI) system spans the entire workflow, enabling real-time data capture and full-process traceability.

 Efficient & On-Time Delivery
Efficient & On-Time Delivery

Highly coordinated operations and refined process management help shorten turnaround time and ensure timely product delivery.

Comprehensive Quality Assurance
Comprehensive Quality Assurance

Manufactured in compliance with cGMP standards and supported by rigorous quality control to ensure product safety, quality, and consistency.

Patient-Centric Experience
Patient-Centric Experience

A patient-centered service model designed to provide a seamless and high-quality treatment experience.